Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Vickers, Andrew J ^a   Sjoberg, Daniel D ^a   Ulmert, David ^a,c   Vertosick, Emily ^a   Roobol, Monique J ^b   Thompson, Ian ^d,e   Heijnsdijk, Eveline A M ^b   De Koning, Harry ^b   Atoria Swartz, Coral ^a   Scardino, Peter T ^a   Lilja, Hans ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

^d University of Texas Health Science Center at San Antonio   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Early detection; Overdiagnosis; Prostate cancer; PSA; Screening

Indexed keywords

AGED; AGED, 80 AND OVER; COHORT STUDIES; EARLY DETECTION OF CANCER; EMPIRICAL RESEARCH; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84893870262     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-26     Document Type: Article

References (29)

1. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157:120-134. 10.7326/0003-4819-157-2-201207170-00459, 22801674.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366:981-990. 10.1056/NEJMoa1113135, 22417251, ERSPC Investigators.
3. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009, 101:374-383. 10.1093/jnci/djp001, 2720697, 19276453.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
5. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008, 64:10-19. 10.1111/j.1541-0420.2007.00825.x, 17501937.
6. Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 2007, 99:1171-1177. 10.1093/jnci/djm060, 17652279.
7. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007, 25:431-436. 10.1200/JCO.2006.06.9351, 17264339.
8. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008, 359:2220-2232. 10.1056/NEJMoa0801869, 19020324.
9. Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, Berglund G, Lilja H. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 2006, 52:235-239.
10. Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010, 341:c4521. 10.1136/bmj.c4521, 2939950, 20843935.
11. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98:529-534. 10.1093/jnci/djj131, 16622122.
12. Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schröder FH, Lilja H. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res 2010, 16:4374-4381. 10.1158/1078-0432.CCR-10-1328, 2937360, 20736330.
13. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012, 367:595-605. 10.1056/NEJMoa1201637, 22894572.
14. Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med 2010, 170:1256-1261. 3651841, 20660846.
15. Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev 2010, 19:1201-1207. 10.1158/1055-9965.EPI-09-1251, 2866147, 20406957.
16. Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, Hugosson J. Lead time associated with screening for prostate cancer. Int J Cancer 2004, 108:122-129. 10.1002/ijc.11554, 14618626.
17. Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol 2012, 61:865-874. 10.1016/j.eururo.2011.11.007, 22104593.
18. Kuller LH, Thomas A, Grandits G, Neaton JD. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:373-377.
19. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994, 344:1594-1598. 10.1016/S0140-6736(94)90405-7, 7527116.
20. Tang P, Sun L, Uhlman MA, Polascik TJ, Freedland SJ, Moul JW. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer 2010, 116:4711-4717. 10.1002/cncr.25447, 20589748.
21. Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995, 87:354-360. 10.1093/jnci/87.5.354, 7531773.
22. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006, 98:1521-1527. 10.1093/jnci/djj410, 2645644, 17077354.
23. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213. 10.1056/NEJMoa1113162, 3429335, 22808955, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group.
24. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, SPCG-4 Investigators Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717. 10.1056/NEJMoa1011967, 21542742, SPCG-4 Investigators.
25. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012, 62:204-209. 10.1016/j.eururo.2012.04.024, 3389180, 22541389.
26. van Leeuwen PJ, Connolly D, Tammela TL, Auvinen A, Kranse R, Roobol MJ, Schroder FH, Gavin A. Balancing the harms and benefits of early detection of prostate cancer. Cancer 2010, 116:4857-4865. 10.1002/cncr.25474, 20839233.
27. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009, 101:1325-1329. 10.1093/jnci/djp278, 2758309, 19720969.
28. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012, 104:1335-1342. 10.1093/jnci/djs299, 3529593, 22835388.
29. Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012, 118:5955-5963. 10.1002/cncr.27594, 3424303, 22605665.